Loading
A virus backbone edited to replicate only in tumour cells and a transgene it carries to call the immune system in. The corpus holds 8 oncolytic viruses medicines: 3 approved, 2 in phase 3, 10 trials recruiting, 10 companies named. Every section below says which records it was read from.
From 1 record:Oncolytic viruses
Viruses engineered to infect and burst cancer cells while leaving normal cells alone, and to alert the immune system in the process.
Attenuated virus replicates selectively in tumour cells (defective antiviral signalling), lysing them and releasing antigens and encoded cytokines.
From 8 records:Cretostimogene grenadenorepvecH101 oncolytic adenovirusOlvimulogene nanivacirepvecT3011Talimogene laherparepvecTHEO-260TILT-123Vusolimogene oderparepvec
Virus backbone against transgene, 2 by 3. Open the grid, where every cell links to its medicines and the records behind its state.
From 3 records:H101 oncolytic adenovirusTalimogene laherparepvecVusolimogene oderparepvec
| H101 oncolytic adenovirus | Adenovirus | 2005 | CN | approved | ||
Talimogene laherparepvec Imlygic | Herpes simplex virus 1 | 2015 | US | approved | ||
Vusolimogene oderparepvec Tudriqev | Herpes simplex virus 1 | 2026 | US | approved |
From 2 records:Cretostimogene grenadenorepvecOlvimulogene nanivacirepvec
| Phase 3 trials here | ||||||
|---|---|---|---|---|---|---|
| Cretostimogene grenadenorepvec | Adenovirus | 2 | phase 3 | |||
| Olvimulogene nanivacirepvec | - | 2 | phase 3 |
From 8 records:Cretostimogene grenadenorepvecH101 oncolytic adenovirusOlvimulogene nanivacirepvecT3011Talimogene laherparepvecTHEO-260TILT-123Vusolimogene oderparepvec
From 10 records:AmgenBristol Myers SquibbOmega FundsReplimuneShanghai Sunway BiotechCG OncologyGeneluxImmVira Pharmaand 2 more in the JSON
| Company | Type | Medicines | Approved | Phase 3 | Which |
|---|---|---|---|---|---|
| Amgen US | pharma | 1 | 1 | 0 | |
| Bristol Myers Squibb US | pharma | 1 | 1 | 0 | |
| Omega Funds US | investor | 1 | 1 | 0 | |
| Replimune US | biotech | 1 | 1 | 0 | |
| Shanghai Sunway Biotech CN | biotech | 1 | 1 | 0 | |
| CG Oncology US | biotech | 1 | 0 | 1 | |
| Genelux US | biotech | 1 | 0 | 1 | |
| ImmVira Pharma CN | biotech | 1 | 0 | 0 | |
| Theolytics GB | biotech | 1 | 0 | 0 | |
| TILT Biotherapeutics FI | biotech | 1 | 0 | 0 |
From 10 records:Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With AdvaA Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBCEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL H101 Plus TACE for r/m HNSCCIntratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaPhase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCand 2 more in the JSON
From no record yet:
No Side effects term is linked from this format's records.
From no record yet:
The resistance atlas records no class whose exemplars are medicines of this format.
From 9 records:Oncolytic virusesCretostimogene grenadenorepvecH101 oncolytic adenovirusOlvimulogene nanivacirepvecT3011Talimogene laherparepvecTHEO-260TILT-123and 1 more in the JSON
No key paper in the corpus is linked to a medicine or technology of this format.
From 1 record:Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
From 9 records:Oncolytic virusesCretostimogene grenadenorepvecH101 oncolytic adenovirusOlvimulogene nanivacirepvecT3011Talimogene laherparepvecTHEO-260TILT-123and 1 more in the JSON
Oncolytic viruses that make interleukin-12 only inside the tumour Interleukin-12 is an immune-stimulating cytokine that caused severe toxicity when injected into the bloodstream in the 1990s and was abandoned. An oncolytic he… | Early clinical | |
Deliver drugs and cells to the brain through the nose The nerves at the top of the nose lead directly into the brain, bypassing the barrier. Nasal delivery of drugs, and even immune cells, has worked in animals. | Preclinical evidence | |
Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours Immunotherapy works in tumours that immune cells can enter and ignores those that shut them out. Systematically test ways to open up the shut-out tumours, meas… | Preclinical evidence |
From no record yet:
Apheresis, vector, closed manufacturing, cryopreservation and chain of identity, release testing, point of care and allogeneic banks.
Apheresis and starting-material collectionViral vector manufacturing (lentiviral, retroviral, AAV)Autologous CAR-T manufacturing, batch by batchClosed automated cell-therapy manufacturingCryopreservation and cell-therapy cold chainCell-therapy orchestration and chain-of-identity softwareCell-therapy release and potency testingPoint-of-care and decentralised cell manufacturingAllogeneic cell banks: one donor, hundreds of doses
CompaniesNovartisGilead Sciences (incl. Kite)Bristol Myers SquibbLegend BiotechAutolus TherapeuticsOXB (Oxford Biomedica)Miltenyi BiotecCytiva (Danaher)LonzaCellaresCryoportTerumo Blood and Cell TechnologiesCellectisAllogene TherapeuticsImmunoACT
| Site | Operator | Capabilities | Makes | Source |
|---|---|---|---|---|
| Kite Frederick Frederick, Maryland, US · in-house | Kite (Gilead) | Cell therapyViral vector | Kite manufacturing | |
| Miltenyi Biotec Bergisch Gladbach, DE · contract manufacturer | Miltenyi Biotec | Cell therapyViral vector | Miltenyi Biotec | |
| Oxford Biomedica Oxbox Oxford, GB · contract manufacturer | Oxford Biomedica | Viral vector | Oxford Biomedica |
The manufacturing map draws every site and the seven supply chains.
No manufacturing technology record is listed for this format.
The medicines are the ones the open drug engine files under oncolytic viruses, whether it placed them on its grid or listed them as unresolved. The technology records are listed by hand (src/lib/modular-formats.ts) and each carries a pill back here. Everything else follows the graph's links from those two sets: approvals, cancers and toxicity from the medicine records; companies, trials, papers and ideas from the records that name a medicine or technology; roadmap steps from their refs; resistance from the atlas; manufacturing from the site and supply chain records.
Nothing here is written for the hub. Where the corpus holds no record for a section, the section says so rather than filling the gap, and the counts are counts of records in OnCo, not of the world. The JSON companion carries every section with the record ids behind it. Not medical advice.